Extensive stage small cell lung cancer is one of the two sub-types of small cell lung cancer. The other type of small cell lung cancer is limited stage small cell lung cancer. Extensive stage small cell lung cancer is defined as a disease that cannot be safely contained in a tolerable radiation field. It is one of the most aggressive diseases, and most small cell lung cancer patients are diagnosed with extensive stage small cell lung cancer. The extensive stage of small cell lung cancer accounts for approximately two-third of small cell lung cancer patients. The disease prognosis is very poor, with median overall survival of limited months.. Cigarette smoking has been found to be the most common cause of lung cancer. Although tumor node metastasis (TNM) staging is available for SCLC, most clinical trials and treatment decisions are based on the Veterans Administration (VA) staging scheme. 

Disease Overview 

Extensive stage small cell lung cancer (ES-SCLC) is one of the two types of small cell lung cancer (SCLC). It is an aggressive disease with high metastatic potential. Most cases of extensive stage small cell lung cancer are diagnosed when it has already metastasized beyond the lung or the area between the lungs or the lymph nodes above the collarbone to other places in the body. The extensive stage small cell lung cancer accounts for approximately two-thirds of the total small cell lung cancer cases. This type of small cell lung cancer has a poor prognosis, with the median overall survival from the time of diagnosis ranging very less months. Approximately five percent of ES-SCLC patients survive two years after diagnosis. According to the TNM system of cancer staging, where T stands for tumor, N stands for node, and M stands for metastasis. Extensive stage small cell lung cancer is classified as stage IV disease.

The Growing Prevalence of Extensive Stage Small Cell Lung Cnacer

The prevalence of Extensive Stage Small Lung Cancer is estimated to increase in five of the seven major markets included in the study. Geographically, the U.S. remains at the top with an estimated prevalence for 2021 of more than 47,000 patients followed by the U.K. with over 8,500 patients. The prevalence is forecasted to be growing at a CAGR of 2.61% and 1.61% respectively for the U.S. and the U.K for the period 2022-2032. 

Market Dynamics

Introduction of Immune Checkpoint Inhibitors in Combination with PlatinumBased Chemotherapy as Mainstay Treatment

For decades, the standard course of treatment for extensive stage small cell lung cancer was platinum-based chemotherapy, until recently, in 2018, when the incorporation of immunotherapy along with platinum-based chemotherapy came into the picture. PD-L1 immunotherapies in combination with etoposide (EP) regimens as first-line treatment for extensive stage small cell lung cancer demonstrated an increase in overall survival (OS) in randomized phase three clinical studies. Following this, two immune checkpoint inhibitors, Imfinzi (Durvalumab) and Tecentriq (Atezolizumab), were approved by the FDA. This combined regimen of immunotherapy plus chemotherapy resulted in increased overall survival as well as increased progression free survival and became the current mainstay of extensive stage small cell lung cancer treatment. Since then, there has been an increased interest in evaluating different immune checkpoint inhibitors in the treatment of extensive stage small cell lung cancer. Currently, there are more than 30 studies evaluating immunotherapies for the treatment of extensive stage small cell lung cancer in different stages

Market Segmentation:

Within the research report, the segmentation has made on the basis of:

  •   Existing as well as Expected competition in the global extensive stage small cell lung cancer market. Commercial and Clinical products constitute “Products” segment., and
    •    Region is the other segment which covers the seven major markets (the U.S., the U.K., Germany, France, Italy, Spain, and Japan).

Get Free Sample Report - https://bisresearch.com/requestsample?id=1407&type=download

Key Companies Profiled

  •   F. Hoffmann-La Roche Ltd
    •    AstraZeneca PLC
    •    Jazz Pharmaceuticals Plc
    •    G1 Therapeutics Inc.
    •    Shanghai Henlius Biotech, Inc.
    •    Lee's Pharmaceutical Limited
    •    Jiangsu Hengrui Pharmaceuticals Co., Ltd.
    •    Beigene Ltd.

Key Questions Answered in the Report

What are the treatments currently available for extensive stage small cell lung cancer patients in the market?

What are the major market drivers, challenges, and opportunities in the global extensive stage small cell lung cancer market?

What does the global extensive stage small cell lung cancer market pipeline look like? 

What is the target patient pool eligible for extensive stage small cell lung cancer treatment in seven major markets?

How is the patient pool in each market expected to grow during the forecast period 2022-2032?Additionally, BIS Research also offers a dedicated and unique platform to find and access deeptech insights and updates on emerging technologies across industry verticals. Insight Monk, an AI powered deeptech search engine, is a subscription based platform that offers a library of latest market insights and updates based on emerging tech. Learn more about InsightMonk here. https://www.insightmonk.com